{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:00:33Z","timestamp":1778864433804,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ajoc.2022.101333","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T03:06:19Z","timestamp":1642820779000},"page":"101333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report"],"prefix":"10.1016","volume":"25","author":[{"given":"Xinyu","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-4670","authenticated-orcid":false,"given":"Daiju","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-851X","authenticated-orcid":false,"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuomi","family":"Mizuuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2022.101333_bib1","series-title":"Guidelines for Management of Vasculitis Syndrome","first-page":"1","author":"Isobe","year":"2017"},{"issue":"10","key":"10.1016\/j.ajoc.2022.101333_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/rheumatology\/kex261","article-title":"Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study","volume":"56","author":"Patompong","year":"2017","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101333_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin Med"},{"key":"10.1016\/j.ajoc.2022.101333_bib4","series-title":"Anca-related Vasculitis Medical Treatment Guideline","first-page":"1","author":"Ozaki","year":"2011"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101333_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Richard","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101333_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0039-6257(88)90093-8","article-title":"Posterior scleritis","volume":"32","author":"Benson","year":"1988","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajoc.2022.101333_bib7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/bjo.2009.171744","article-title":"Clinical features and visual outcomes of Japanese patients with scleritis","volume":"94","author":"Keino","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101333_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101333_bib9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101333_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2012.08.005","article-title":"Visual outcome, treatment results, and prognostic factors in patients with scleritis","volume":"120","author":"Wieringa","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101333_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ophtha.2003.06.006","article-title":"Evaluation of patients with scleritis for systemic disease","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101333_bib12","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00417-014-2696-1","article-title":"Five-year outcome in immune-mediated scleritis","volume":"252","author":"Bernauer","year":"2014","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101333_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajoc.2022.101333_bib14","series-title":"Clinical Practice Guideline for ANCA-Associated Vasculitis","first-page":"1","author":"Arimura","year":"2017"},{"issue":"5","key":"10.1016\/j.ajoc.2022.101333_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101333_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101333_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and safety of biological DMARDs modulating B cells in primary Sj\u00f6gren\u2019s syndrome: systematic review and meta-analysis. Joint Bone Spine","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ajoc.2022.101333_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-016-0951-z","article-title":"Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration","volume":"18","author":"Chatzidionysiou","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101333_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust Prescr"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101333_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajoc.2022.101333_bib21","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00417-015-3198-5","article-title":"Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's)","volume":"253","author":"Recillas-Gispert","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101333_bib22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","article-title":"Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener's)","volume":"26","author":"You","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"6 Pt 2","key":"10.1016\/j.ajoc.2022.101333_bib23","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.lpm.2015.04.008","article-title":"Update on the management of ANCA-associated vasculitis","volume":"44","author":"Smith","year":"2015","journal-title":"Presse Med"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:02:59Z","timestamp":1762527779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"alternative-id":["S2451993622000792"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101333","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101333"}}